Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa Open-Label Study of Rituximab in Pediatric GPA and MPA
2012-002062-13Phase 2Completed
- Sponsor
- Roche
- Start
- Aug 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), sponsored by Roche. Primary endpoints: Safety and tolerability and Pharmacokinetics of rituximab. Started Aug 2012; status: completed.
02
Drugs
rituximab
03
Conditions
granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)
Beyond the preview
Go deeper on 2012-002062-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002062-13.